MAPK8 and neoplasm: Our results suggest that JNK1/2 activation following Rigosertib treatment cannot only block tumor cell growth via the inhibition of RAS/RAF/MEK/ERK signaling, but also additionally through unleashing p66Shc-dependent ROS stress.